hydroxychloroquine - versus placebo - for COVID-19 prophylaxis   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.98 [0.02, 49.67]< 10%1 study (1/-)50.3 %lownot evaluable highcrucial-
conversion to SARS-CoV- 2–positive status via NP swab 1.57 [0.93, 2.64]< 10%4 studies (4/-)4.6 %some concernnot evaluable moderateimportant-
hospitalization 0.98 [0.06, 15.77]< 10%1 study (1/-)50.5 %lownot evaluable highimportant-
new illness compatible with Covid-19 0.76 [0.59, 0.99]< 10%3 studies (3/-)98.0 %lownot evaluable highimportant-
PCR-confirmed, symptomatic Covid-19 disease 0.93 [0.45, 1.90]< 10%3 studies (3/-)58.2 %some concernnot evaluable moderateimportant-

-- safety endpoints 00

adverse events 1.69 [0.54, 5.29]< 197%3 studies (3/-)18.4 %lownot evaluable highnon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 89 89